Nanosonics Limited Overview
Nanosonics is an Australian-founded medical technology company that created, and still leads, the category of automated high-level disinfection (HLD) for ultrasound probes. Its trophon platform uses a sonically activated hydrogen-peroxide mist and has a global cumulative installed base of 39,230 units, about 87% of which are in North America. The company estimates that trophon protects more than 31 million patients a year. The business follows a classic razor/razor-blade model: roughly 73% of FY26 revenue (A$149.2M of A$203.9M) was recurring, coming from proprietary consumables, service, traceability software and spare parts, with gross margins near 77%. Nanosonics is debt-free with A$155.2M in cash. It is now commercialising its second platform, the CORIS System, which is the first automated technology for cleaning the internal channels of flexible endoscopes. CORIS holds FDA De Novo and 510(k) clearances, CE and UKCA marks, and ARTG inclusion. Management's stated ambition is to become a multi-platform global infection-prevention company. The near-term investment case depends on balancing trophon's cash generation against the cost of scaling CORIS.
Company's own description (FY26 Annual Report, paraphrased)
The FY26 Annual Report describes Nanosonics as a global leader in automated infection-prevention solutions for medical device reprocessing. It presents trophon as the technology that set a new standard for HLD of ultrasound probes, delivering validated, repeatable and efficient reprocessing while reducing procedural variability. It describes the CORIS System as a groundbreaking automated technology for flexible endoscope cleaning that is now moving into commercialisation. The company operates across North America, Europe, the UK and Asia Pacific.
The Directors' Report lists two principal activities:
-
Manufacturing, servicing and distributing the trophon ultrasound probe disinfector and its consumables and accessories.
-
Researching, developing and commercialising infection control and decontamination products and related technologies.
The company's mission is to improve the safety of patients, clinics, their staff and the environment by changing how infection-prevention practice is understood and conducted.
Business model and revenue model
| Revenue stream | Definition (company) | FY26 AUD Mn | Share of revenue |
|---|---|---|---|
| Capital Revenue | Sale of trophon devices: new installed-base units, upgrades of trophon EPR to trophon2/3, and trophon2 Plus software upgrades | 54.7 | 26.8% |
| Recurring Revenue | Core and ecosystem consumables, service and repairs, and spare parts | 149.2 | 73.2% |
| of which Annuity Revenue | Recurring Revenue excluding spare parts. Adopted in FY26 as a key corporate metric and a short-term incentive (STI) metric. | 141.8 | 69.5% |
Nanosonics reports two revenue streams, and from FY26 it also tracks a third KPI:
Breaking revenue down by type of offering (analyst characterisation):
Product, capital equipment: about 27% of revenue (devices plus upgrade software).
Product, consumables: about 53% of revenue. Core consumables (Sonex/NanoNebulant hydrogen-peroxide cartridges and chemical indicators) were A$92.6M, and ecosystem consumables and accessories were A$15.8M.
Service: about 16% of revenue (A$33.4M), covering repairs, maintenance contracts and traceability services such as Nanosonics Connect. Service grew 14% reported, or 19% in constant currency, in FY26.
Spare parts: about 4% of revenue (A$7.4M derived). This line is declining as older units are retired.
Subscription / SaaS: Nanosonics Connect is a cloud-based traceability offering. Its revenue is reported inside service and not broken out separately.
Licensing: No material licensing revenue is disclosed.
Commercial models. In the US, Nanosonics sells directly. It moved to direct sales in 2019, after a long period in which GE Healthcare acted as distributor and later capital reseller. Customers can buy devices outright, rent them (common in Japan), or take a managed equipment service (MES) contract (prominent in the UK, with no upfront capital component). In FY26 the company won a Premier, Inc. group purchasing organisation (GPO) agreement for trophon3, effective 1 March 2026.
Value-chain position
Nanosonics is a vertically integrated original equipment manufacturer (OEM). It owns the IP, designs the devices and the proprietary chemistry, manufactures devices and consumables, distributes directly in its major markets, and provides field service and digital traceability. Upstream, it relies on contract and sole-source component suppliers, which the company flags as a material risk. In FY26 it brought manufacture of its core consumable, Sonex, in-house at its Indianapolis site. Downstream, it sells to hospital infection-prevention, radiology/imaging, women's health and emergency departments, as well as private physician offices.
A distinctive feature is the probe compatibility program. trophon is validated for more than 1,400 ultrasound probes from more than 30 ultrasound OEMs, which embeds Nanosonics in OEM reprocessing instructions.
Customer types and end-markets
| End-market | Customers | Product |
|---|---|---|
| Ultrasound probe reprocessing (semi-critical devices: endocavitary and surface probes) | Hospitals (radiology, OB/GYN, urology, emergency, ICU), outpatient imaging centres, private physician offices | trophon EPR, trophon2, trophon3, trophon2 Plus, consumables, Nanosonics Connect |
| Flexible endoscope reprocessing (channel cleaning step) | Hospital endoscopy units and central sterile services departments | CORIS System and CORIS QUANTUM consumable |
| Government / defence health | e.g., the US Defense Health Agency buys sole-source trophon2 service at military hospitals | trophon service |
Independent characterisation
Nanosonics is a "category creator" with a single cash-generating franchise. That franchise is highly penetrated in the US hospital setting, so growth now depends on four things:
-
The upgrade cycle. About 8,000 original EPR units remain in North America, and about 20,000 trophon2 units are candidates for trophon2 Plus software upgrades.
-
Physician-office and international penetration, which has been slow outside North America.
-
Pricing and service attachment.
-
CORIS, which is the real long-term growth option.
The business carries a structurally high gross margin of 76–79%. However, operating margins are held down by heavy R&D and CORIS spending: CORIS consumed A$34.6M of operating expense in FY26 against zero revenue. Measured on a "trophon-only" basis, EBIT margin was about 25% in FY26 (derived), which shows the franchise's underlying economics.
Strategy
Stated corporate strategy (FY26 Annual Report themes, paraphrased)
Ambition: Build Nanosonics into a broader global infection-prevention company with multiple technology platforms addressing complex reusable-device workflows. Management describes FY26 as the start of a "defining period of growth".
Two sources of value: 1. Continued expansion and lifecycle value of trophon, through installed-base growth, upgrades, trophon2 Plus software, consumables, service and traceability.
- CORIS as a second major growth engine.
Capability claim: Nanosonics' repeatable strengths are category creation, installed-base economics, recurring revenue, high gross margins, regulatory execution and disciplined investment.
Capital allocation: Fund R&D and the CORIS launch from trophon cash flow. Assess bolt-on M&A that is strategically aligned and financially disciplined. Return capital through buy-backs.
Industry tailwinds cited: Demand for validated, audit-ready processes; care shifting to outpatient and ambulatory settings; purchasing focused on risk reduction and workflow; and the growing importance of digital traceability and cybersecurity.
Strategic initiatives in the last 24 months
| Initiative | Timing | Detail / status |
|---|---|---|
| trophon3 and trophon2 Plus next-generation platform | Jul–Aug 2025 launch | More than 40% faster cycle and DICOM/HL7 traceability. Second-half FY26 adoption accelerated; pricing improved. |
| Nanosonics Connect, DICOM integration and mobile app | FY25–FY26 | Digital traceability ecosystem; service revenue +19% CC in FY26 |
| CORIS phased commercialisation | Dec 2025 approvals; CMR from Feb 2026; launch H1 FY27 | UK, Ireland and Australia first, then the US. Second 510(k) under FDA review. |
| CORIS investment step-up | FY27 | FY27 opex guided +10–15%, explicitly for market awareness, pipeline building and early adoption |
| US manufacturing localisation (Indianapolis) | FY26 | Sonex insourced; CORIS QUANTUM to follow. Supports tariff mitigation, supply resilience and lower Scope 3 emissions. |
| Premier GPO contract | Effective 1 Mar 2026 | Pre-negotiated trophon3 pricing for Premier member facilities |
| Japan market development | Ongoing | Pursuing national HLD guidelines and trophon3 regulatory clearance |
| Capital management | A$20M buy-back (Nov 2025–FY26, completed); A$40M buy-back in FY27 | First-ever capital returns |
| Cybersecurity | Ongoing | ISO 27001:2022 recertification; NIST CSF 2.0 and Essential Eight overlay; HITRUST certification in progress for the US |
| Sustainability | FY26–FY27 | Scope 1 and 2 emissions down 49%; AASB S2 climate disclosure compliance from FY27 |
| Incentive realignment | FY26 | Annuity Revenue adopted as a key metric; FY27 executive KMP share three common non-financial strategic measures |
Management guidance and medium-term targets
| Item (FY27, constant currency) | Range | Growth vs FY26 |
|---|---|---|
| Revenue | A$220M–A$228M | +8% to +12% |
| Gross margin | 74%–76% | down from 76.9% |
| Operating expenses | A$156M–A$163M | +10% to +15% |
| CORIS revenue | "Low single-digit millions" | first revenue |
Products & Services
trophon platform (ultrasound probe high-level disinfection)
| Product | Description and key capabilities | Target customer | Launch / latest version | Pricing model |
|---|---|---|---|---|
| trophon EPR | First-generation automated HLD device using a sonically activated hydrogen-peroxide mist in an enclosed chamber; residual mist is converted to water and oxygen | Hospitals, imaging | First sales Mar 2009; FDA 2011. Now legacy, with about 8,000 units remaining in North America as upgrade candidates. | Capital sale (historically via GE); consumables per cycle |
| trophon2 | Second generation with redesigned hardware and AcuTrace digital record-keeping, plus hospital IT connectivity | Hospitals, outpatient, physician offices | c. 2018; about 20,000 units globally | Capital, rental or MES; consumables; service contracts |
| trophon3 | Next generation. Cycle time is more than 40% faster (marketed as a 4-minute HLD cycle). Offers expanded digital integration, RIS/PACS/DICOM traceability, HL7 messaging and full programmability. | All ultrasound settings, including point-of-care | EU/UK/ANZ/Canada Jul 2025; US Aug 2025 after FDA clearance; on Premier GPO contract from 1 Mar 2026 | Capital or rental. Second-half FY26 pricing improved as trophon3's share of sales rose. |
| trophon2 Plus | Software upgrade that brings key trophon3 features (including the 4-minute cycle, activated remotely via software v1.9) to installed trophon2 units | About 20,000 existing trophon2 owners | Jul 2025 (ex-US) / Aug 2025 (US); uptake accelerated in Q4 FY26 | Software upgrade fee, counted in Capital Revenue; management expects meaningful FY27 revenue |
| Sonex / NanoNebulant | Proprietary hydrogen-peroxide consumable cartridge. Manufacturing insourced at Indianapolis in FY26. | Every trophon user | Ongoing | Per-cycle consumable; the core annuity stream |
| Chemical indicators (e.g., AcuTrace CI) | Per-cycle independent verification of disinfection | Every trophon user | Ongoing | Consumable |
| Ecosystem products | Accessories such as probe covers/holders, printers, operator cards and storage | trophon users | Ongoing | Consumable/accessory (A$15.8M in FY26) |
| Software releases (v1.9 Sep 2025; v1.10 Jun 2026) | Security, reliability and traceability enhancements, including certification via Nanosonics Academy | Installed base | Sep 2025 / Jun 2026 | Included in service/upgrade |
Digital and traceability
| Product | Description | Status |
|---|---|---|
| Nanosonics Connect | Cloud-based traceability across devices and facilities, with real-time compliance monitoring; replaces paper logbooks | Commercial; revenue sits inside the service line |
| Traceability via DICOM | Integrates with Modality Worklist/PACS so that each disinfection record is linked to the imaging study | Launched with trophon3 |
| Nanosonics Connect Mobile app | Captures records on iOS/Android for emergency, ICU and point-of-care workflows | Commercial |
| AuditPro | Infection-control workflow compliance management system | Commercial |
| AcuTrace | Device-level digital record-keeping on trophon2/3 | Commercial |
Service offerings
These include multi-year service and maintenance contracts (historically attached to about half of new US unit sales, per Forager Funds), repairs, spare parts, training (Nanosonics Academy) and sole-source OEM service, for example to the US Defense Health Agency.
CORIS platform (flexible endoscope channel cleaning)
| Element | Description |
|---|---|
| CORIS device | Automated, validated and traceable cleaning of internal endoscope channels, including narrow, branched and unbrushable channels where biofilm forms. Uses CORIS PULSS (Pulsed Suspended Solids) technology to create controlled physical friction. Requires plumbing installation, so hospital sales cycles are longer than for trophon. |
| CORIS QUANTUM | Proprietary cleaning-agent consumable. To be manufactured globally at Indianapolis in due course. |
| Accessories and future digital | Accessories plus planned traceability and compliance capabilities |
| Regulatory status | US: FDA De Novo (Class II) granted March 2025 for an initial Olympus EVIS colonoscope indication; first 510(k) for expanded endoscope indications cleared 9 Mar 2026; second 510(k) submitted May 2026 and under review. EU: CE mark. UK: UKCA. Australia: ARTG (all Dec 2025). |
| Commercial status | CMRs have been running in the UK (from Feb 2026), Australia (from May 2026), Ireland and the US. Commercial launch is planned for the UK, Ireland and Australia in H1 FY27, with the US to follow. FY27 CORIS revenue is guided at "low single-digit millions". |
| Pricing | Not publicly disclosed. The model mirrors trophon: capital, proprietary consumables, service and digital. |
Financial Narrative
Income statement: notes and sources
Source: FY26 Annual Report five-year table (A$'000 rounded). The FY24 tax expense was A$14k. "Other income" from the NSW Jobs Plus Program was A$1.5M in FY26 and A$1.3M in FY25.
Per-share data
Sources: FY26 and FY25 basic EPS of 5.90c and 6.82c from the Appendix 4E (via StockLight). FY23 and FY24 from InvestSMART (aggregator). FY22 is derived (NPAT ÷ about 301M shares). InvestSMART shows FY25 EPS as 6.7c, which differs from the 6.82c attributed to the 4E; the 4E figure is preferred. No dividends have been paid; the FY26 Directors' Report confirms nil for both FY26 and FY25.
Margins and growth
Gross margin is as reported. Other ratios are derived. Constant-currency growth was disclosed only for FY26; the zeros in earlier years mean "not disclosed", not zero growth. The company itself rounds FY26 R&D intensity to 16% (FY25: 17%).
Revenue CAGR FY22–FY26 (4 years): 14.1% (derived). EBITDA CAGR FY22–FY26: 34.7% (derived, flattered by the depressed FY22 base).
Balance sheet
Cash figures are from the FY26 Annual Report. Other rows are from Kalkine Media (aggregator). The full statements are in the FY26 Annual Report (pages 62–97).
Additional balance-sheet facts:
Borrowings: None. The company states "no debt on the balance sheet". Lease liabilities (property) are the only debt-like items; InvestSMART shows about A$7.7M of total lease-type debt for FY25, of which A$4.3M is long-term.
Equity: About A$209.9M at 30 June 2025 (InvestSMART). FNArena's book value per share of 69.1c × 303.6M shares gives about A$209.8M, which is consistent.
Goodwill: Effectively nil. The company has made no acquisitions.
Working capital: FY26 cash flow included increased inventory investment for trophon growth and the CORIS launch.
Cash flow: notes and sources
Source: FY26 Annual Report page 15. Operating cash flow and capex were not split out in the sources retrieved. FNArena shows net operating cash flow of A$44.0M on a trailing basis that appears to correspond to FY25. A US-dollar aggregator (Digrin) shows free cash flow of US$13.2M for H2 FY25 and US$2.9M for H1 FY26, which signals much weaker FY26 cash conversion. Full statutory cash-flow figures are in the FY26 Annual Report.
Return and efficiency ratios
Derived from aggregator total assets.
Other ratios:
ROE: About 9.9% in FY25 (NPAT A$20.7M ÷ equity about A$209.9M, derived).
Underlying ROE (company LTI metric): 29.5% for the 2022 LTI award period. This is a company-defined measure that is not comparable to statutory ROE.
ROIC: Not meaningful in a conventional sense. Invested capital excluding cash is small, so ROIC on operating capital is very high. A precise figure was not computed because FY26 balance-sheet detail is missing.
Debt/equity, net debt/EBITDA, interest coverage: Not meaningful. The company is net cash and has no borrowings.
- For FY25, current assets of A$225.3M against total liabilities of about A$62.6M (derived from aggregator assets less equity) imply a current ratio comfortably above 3x.
Cash conversion cycle: Not publicly disclosed.
Commentary: trends, inflections and drivers
FY22, the trough. Revenue grew only modestly to A$120.3M and EBIT fell to A$1.8M (margin 1.5%). This reflected disruption from changes to the US go-to-market model, which shifted volume away from GE Healthcare capital reselling, combined with rising CORIS investment (A$14.4M of opex).
FY23, the rebound. Revenue jumped 38% to A$166.0M. Capital revenue rose 44% as placements reached 4,410 units, including 1,810 upgrades, and recurring revenue rose 35%. EBIT recovered to A$19.6M.
FY24, the pause. Revenue grew only 2.4%. Capital revenue fell 11% as upgrades slowed to 1,510 and new installed-base placements slipped to 2,340. Opex kept rising, so EBIT halved to A$9.1M. This was the low point in investor sentiment and coincided with CORIS regulatory delays.
FY25, operating leverage. Revenue rose 16.8% to A$198.6M, led by recurring revenue (+20%, with service +23%). EBIT nearly doubled to A$17.8M and NPAT reached a record A$20.7M. Cash rose A$32.0M to A$161.6M.
FY26, currency-masked progress. Reported revenue grew 3% but constant-currency growth was 6%. The average USD/AUD rate moved from 0.65 to 0.68, and about 91% of revenue is from North America in US dollars, so the stronger Australian dollar mechanically compressed the reported numbers. Gross margin slipped 1.3 points to 76.9% because of mix (more capital, more upgrades) and currency. US tariffs were mostly recovered: A$2.5M of tariffs paid under the International Emergency Economic Powers Act (IEEPA) up to February 2026 were refunded, leaving A$0.6M of residual tariff cost. R&D fell 8% to A$31.8M as CORIS moved from development to commercialisation, while CORIS opex rose 13% to A$34.6M. Reported EBIT fell 10% to A$16.0M, but constant-currency EBIT rose 21% to A$21.6M.
Inflection for FY27. Guidance implies another deliberate dip in profit. At the midpoints (revenue A$224M, gross margin 75%, opex A$159.5M), implied EBIT is about A$8.5M before other income (analyst derivation, constant currency). Tariffs at 12.5% for a full year and higher freight costs are expected to push gross margin down to 74–76%.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Revenue by Segment (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Capital Revenue (AUD Mn) | 37.7 | 54.2 | 48.2 | 52.5 | 54.7 |
Recurring Revenue (AUD Mn) | 82.7 | 111.8 | 121.8 | 146.1 | 149.2 |
Total Revenue (AUD Mn) | 120.3 | 166.0 | 170.0 | 198.6 | 203.9 |
Capital share of revenue (%) | 31.3 | 32.7 | 28.4 | 26.4 | 26.8 |
Recurring share of revenue (%) | 68.7 | 67.3 | 71.6 | 73.6 | 73.2 |
Capital Revenue YoY growth (%) | — | 43.8 | -11.1 | 8.9 | 4.2 |
Recurring Revenue YoY growth (%) | — | 35.2 | 8.9 | 20.0 | 2.1 |
Revenue by Segment
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Core consumables (AUD Mn) | 56.6 | 77.9 | 80.4 | 92.2 | 92.6 |
Ecosystem consumables and accessories (AUD Mn) | 7.9 | 10.8 | 11.8 | 15.1 | 15.8 |
Service incl. Nanosonics Connect (AUD Mn) | 12.4 | 16.9 | 24.0 | 29.4 | 33.4 |
Annuity Revenue total (AUD Mn) | 76.9 | 105.6 | 116.2 | 136.7 | 141.8 |
Spare parts, derived (AUD Mn) | 5.8 | 6.2 | 5.6 | 9.4 | 7.4 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment and Segment Margins & Growth (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total opex (AUD Mn) | 90.5 | 114.2 | 125.6 | 138.7 | 141.4 |
trophon opex (AUD Mn) | 76.1 | 91.7 | 98.2 | 108.1 | 106.8 |
CORIS opex (AUD Mn) | 14.4 | 22.5 | 27.4 | 30.6 | 34.6 |
Group EBIT (AUD Mn) | 1.8 | 19.6 | 9.1 | 17.8 | 16.0 |
trophon-only EBIT (AUD Mn) | 16.2 | 42.1 | 36.5 | 48.4 | 50.6 |
trophon-only EBIT margin (%) | 13.5 | 25.4 | 21.5 | 24.4 | 24.8 |
Income Statement
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (AUD Mn) | 120.3 | 166.0 | 170.0 | 198.6 | 203.9 |
Gross profit (AUD Mn) | 91.9 | 130.6 | 132.4 | 155.4 | 156.8 |
R&D expense (AUD Mn) | 22.4 | 29.5 | 32.8 | 34.7 | 31.8 |
Total operating expenses (AUD Mn) | 90.5 | 114.2 | 125.6 | 138.7 | 141.4 |
EBITDA (AUD Mn) | 7.5 | 26.8 | 16.7 | 25.9 | 24.7 |
D&A, derived (AUD Mn) | 5.7 | 7.2 | 7.6 | 8.1 | 8.7 |
EBIT / operating income (AUD Mn) | 1.8 | 19.6 | 9.1 | 17.8 | 16.0 |
Net finance income, derived (AUD Mn) | -0.2 | 2.0 | 3.9 | 4.5 | 4.1 |
Profit before tax (AUD Mn) | 1.6 | 21.6 | 13.0 | 22.3 | 20.1 |
Income tax benefit / (expense) (AUD Mn) | 2.2 | -1.7 | 0.0 | -1.6 | -2.3 |
Net profit after tax (AUD Mn) | 3.7 | 19.9 | 13.0 | 20.7 | 17.8 |
Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Basic EPS (A cents) | 1.2 | 6.5 | 4.2 | 6.8 | 5.9 |
Dividends per share (A cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth YoY (%) | 16.6 | 38.0 | 2.4 | 16.8 | 2.7 |
Constant-currency revenue growth (%) | 0 | 0 | 0 | 0 | 6.0 |
Gross margin (%) | 76.4 | 78.7 | 77.9 | 78.2 | 76.9 |
EBITDA margin (%) | 6.2 | 16.1 | 9.9 | 13.0 | 12.1 |
EBIT margin (%) | 1.5 | 11.8 | 5.4 | 9.0 | 7.8 |
PBT margin (%) | 1.3 | 13.0 | 7.6 | 11.2 | 9.9 |
Net margin (%) | 3.1 | 12.0 | 7.6 | 10.4 | 8.7 |
R&D / revenue (%) | 18.6 | 17.8 | 19.3 | 17.5 | 15.6 |
Opex / revenue (%) | 75.2 | 68.8 | 73.9 | 69.8 | 69.3 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and cash equivalents (AUD Mn) | 94.5 | 112.2 | 129.6 | 161.6 | 155.2 |
Total assets, aggregator (AUD Mn) | 187.7 | 219.9 | 241.9 | 272.5 | 0 |
Total current assets, aggregator (AUD Mn) | 151.3 | 181.6 | 197.8 | 225.3 | 0 |
Net receivables, aggregator (AUD Mn) | 28.4 | 38.8 | 40.6 | 32.3 | 0 |
Goodwill and intangibles, aggregator (AUD Mn) | 0.2 | 0.1 | 0.0 | 0.0 | 0 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Net change in cash (AUD Mn) | -2.2 | 17.1 | 17.4 | 32.0 | -6.4 |
Buy-back cash outflow (AUD Mn) | 0 | 0 | 0 | 0 | 20.0 |
Net change in cash excluding buy-back (AUD Mn) | -2.2 | 17.1 | 17.4 | 32.0 | 13.6 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROA, NPAT / total assets (%) | 2.0 | 9.0 | 5.4 | 7.6 | 0 |
Asset turnover, revenue / total assets (x) | 0.64 | 0.75 | 0.70 | 0.73 | 0 |
Revenue by Region
| Region | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
North America total (AUD Mn) | 106.9 | 150.3 | 154.2 | 180.4 | 186.4 |
Europe, UK and Middle East total (AUD Mn) | 7.5 | 8.1 | 10.1 | 12.2 | 12.3 |
Asia Pacific total (AUD Mn) | 5.9 | 7.5 | 5.8 | 6.0 | 5.1 |
Group total (AUD Mn) | 120.3 | 166.0 | 170.0 | 198.6 | 203.9 |
Revenue by Region by Region / Stream
| Region / stream | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
North America capital (AUD Mn) | 33.6 | 48.9 | 45.0 | 49.4 | 52.3 |
North America recurring (AUD Mn) | 73.3 | 101.4 | 109.2 | 131.0 | 134.1 |
EMEA capital (AUD Mn) | 2.1 | 1.9 | 1.8 | 2.0 | 1.5 |
EMEA recurring (AUD Mn) | 5.4 | 6.2 | 8.3 | 10.2 | 10.8 |
APAC capital (AUD Mn) | 1.9 | 3.3 | 1.5 | 1.1 | 0.9 |
APAC recurring (AUD Mn) | 4.0 | 4.2 | 4.3 | 4.9 | 4.2 |
Region Margins & Growth (%) and Revenue by Region (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
North America revenue growth (%) | 2.6 | 17.0 | 3.3 |
EMEA revenue growth (%) | 24.7 | 20.8 | 0.8 |
APAC revenue growth (%) | -22.7 | 3.4 | -15.0 |
North America share of group (%) | 90.7 | 90.8 | 91.4 |
EMEA share of group (%) | 5.9 | 6.1 | 6.0 |
APAC share of group (%) | 3.4 | 3.0 | 2.5 |
Region Overview
| Region | Cumulative installed base | Growth (%) | New installed-base units | Upgrade units | Total placements |
|---|---|---|---|---|---|
North America | 34,210 | 6 | 1,900 | 1,980 | 3,880 |
EMEA | 2,630 | 8 | 200 | not disclosed (declining) | — |
APAC | 2,390 | 6 | 130 | 20 | 150 |
Global | 39,230 | 6 | 2,230 | 2,000 | 4,230 |
“—” = not publicly disclosed.
Geographic Revenue
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
New installed-base units | 3,100 | 2,600 | 2,340 | 2,210 | 2,230 |
Upgrade units | 1,000 | 1,810 | 1,510 | 1,660 | 2,000 |
Total placements | 4,100 | 4,410 | 3,850 | 3,870 | 4,230 |
Cumulative installed base, derived | 29,850 | 32,450 | 34,790 | 37,000 | 39,230 |
Share Price History
| Date | Price (AUD) | Note |
|---|---|---|
20 Mar 2025 | 4.95 | 52-week high on CORIS De Novo (intraday) |
7 Jul 2025 | 3.85–3.96 | trophon3 launch |
1 Jan 2026 | 3.94 | 2026 opening price |
24 Feb 2026 | about 3.75 | Before H1 results |
6 Mar 2026 | 3.44 | — |
16 Jun 2026 | 3.20 | — |
24 Aug 2026 | 3.68 | Day before FY26 results |
25 Aug 2026 | 3.05 | −17.1% on FY26 results |
2 Sep 2026 | 2.69 | About the 2026 low (intraday A$2.64) |
11 Sep 2026 | 2.76 | Latest retrieved price |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market capitalisation | about A$825M | 298.9M shares |
Enterprise value | about A$670M | Market cap less A$155.2M cash; leases excluded |
P/E (FY26 basic EPS 5.90c) | about 46.8x | Trailing |
EV / Sales (FY26) | about 3.3x | Trailing |
EV / EBITDA (FY26, A$24.7M) | about 27.1x | Trailing |
EV / EBIT (FY26, A$16.0M) | about 41.9x | Trailing |
P/B | about 4.0x | — |
Analyst Ratings & Targets
| Date | Source | Rating | Target (AUD) |
|---|---|---|---|
Jul 2025 | RBC Capital Markets (via IG) | Positive | 5.00 |
24 Feb 2026 | Broker (Investing.com aggregation) | Buy | 5.55 (maintained) |
25 Feb 2026 | Broker (Investing.com aggregation) | Hold | 4.00 → 3.75 |
Feb 2026 | FNArena consensus | Mixed | 3.80 average |
| 2026 | Simply Wall St narrative consensus | — | 5.43 (cut from 6.18) |
17 Jul 2026 | Broker (Investing.com aggregation) | Hold | 3.75 → 3.50 |
Analyst Conclusions
Management guidance (FY27, constant currency)
Revenue A$220–228M (+8–12%); gross margin 74–76%; opex A$156–163M (+10–15%); CORIS revenue in the low single-digit millions; tariff assumed at 12.5%; reported revenue about A$3M lower at USD/AUD 0.71 after hedging. Applying these midpoints implies FY27 EBIT of roughly A$8–10M before other income, versus A$16.0M in FY26 (analyst derivation). Interest on roughly A$115–155M of cash after buy-backs will support pre-tax profit.
Consensus growth expectations
Pre-results consensus EV/Sales of about 3.4x for FY27 implied consensus revenue of about A$230–235M. The guidance midpoint of A$224M (constant currency), and about A$221M reported, therefore sits below pre-results expectations, which helps explain the 17% share-price fall.
Bull case
-
trophon upgrade super-cycle. About 8,000 EPR units, about 20,000 trophon2 units eligible for trophon2 Plus, and Premier GPO access can drive capital revenue growth well above the FY26 rate of +8% at constant currency, with improving pricing as trophon3's share of sales rises.
-
CORIS replicates trophon. It is the first automated channel-cleaning system with a De Novo-created category, recurring QUANTUM consumables, about 60 million global procedures, and a team with direct endoscope-reprocessing experience (Haydon, Wright). Even modest adoption from FY28 could add a second high-margin annuity stream.
-
Valuation support. About A$155M of net cash (about 19% of market capitalisation), a trophon-only EBIT run-rate of A$50–56M, and A$40M of buy-backs (about 5% of shares) mean the core franchise is valued at about 13–14x trophon-only EBIT on enterprise value. That leaves CORIS as a cheap option.
Bear case
-
Core maturation. North American installed-base growth is only 6% a year, new installed-base placements have plateaued at about 2,200 a year since FY24, and APAC is shrinking. Once upgrades are exhausted, trophon becomes a mid-single-digit grower facing patent expiry and cheaper alternatives (Germitec UV-C, Tristel ULT).
-
CORIS as a cash sink. CORIS opex has risen every year (A$14.4M to A$34.6M) and is guided higher. Timelines have already slipped from "H2 FY26 launch" to "throughout FY27, US later". Plumbing-dependent installs and multi-step 510(k) scope expansion lengthen the adoption curve.
-
Margin squeeze. Tariffs (12.5%), freight and a strong Australian dollar compress gross margin to 74–76% while opex rises 10–15%, roughly halving FY27 EBIT. At about 47x trailing P/E there is little room for further disappointment.
Catalysts and monitorables (next 12 months)
-
CORIS commercial launch in the UK, Ireland and Australia in H1 FY27: first orders, reference sites and pricing.
-
FDA decision on the second CORIS 510(k), and timing of the US commercial launch.
-
trophon2 Plus upgrade conversion rate and its contribution to revenue.
-
North American placements and upgrades in the H1 FY27 result (February 2027).
-
Gross margin versus the 74–76% guidance, particularly the effect of tariffs and freight.
-
Pace of execution of the A$40M buy-back.
-
2026 AGM: NED fee-pool vote and any strategy update.
-
Any bolt-on M&A announcement.
-
Movements in the AUD/USD exchange rate.
-
Japan regulatory clearance for trophon3 and adoption of national guidelines.
-
Competitive moves by Germitec and Tristel in US hospitals.
Analyst verdict
Nanosonics enters FY27 as two businesses under one ticker. The first is a mature, high-quality franchise: trophon earns A$50–56M of EBIT on about A$204M of revenue, with 73% recurring revenue, gross margins in the high 70s and a protected installed base of 39,230 units. FY26 showed this engine is still compounding underneath a strong Australian dollar. Constant-currency revenue grew 6%, Annuity Revenue 8%, service 19%, and trophon-only EBIT 16%, while North American upgrades hit a record. The trophon3 and trophon2 Plus cycle has only begun to contribute.
The second business is CORIS, a genuinely novel, De Novo-classified technology in a large and underserved workflow. After roughly A$130M of cumulative operating investment, it is only now reaching commercial launch, and later than first guided. Management has chosen to accelerate spending rather than harvest margins. FY27 guidance therefore implies a sharp fall in EBIT just as tariffs and freight compress gross margin. The market reacted harshly, pushing the shares down 17% on the day and about 30% year-to-date.
At about A$2.76, the valuation is about 3.3x EV/Sales and roughly 13–14x enterprise value to trophon-only EBIT. That looks undemanding for the core franchise, provided trophon does not erode. The net-cash balance sheet and A$40M buy-back limit downside risk to the balance sheet, but not to earnings.
The investment case now depends on evidence rather than narrative. Specifically, investors should watch whether CORIS converts CMR sites into paying customers in the UK and Australia in H1 FY27, whether the FDA clears the second 510(k) on time, and whether the upgrade cycle holds capital revenue growth near the high single digits.
On balance, the risk/reward is asymmetric but slow-burning. The analyst stance is constructive with a 12–24 month horizon: accumulate on proof points, with the clear caveat that profit is likely to fall in FY27 and patience is required.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Independence | Background and other boards |
|---|---|---|---|---|
Steven Sargent | Chairman | Director 6 Jul 2016; Chair Jul 2022 | Independent | 22 years at General Electric (healthcare, energy, financial services). NED of Ramsay Health Care and Ramsay Générale de Santé. Former Chair of OFX Group; former NED of Veda and Origin Energy. BBus (Charles Sturt), FAICD. |
Michael Kavanagh | CEO & President, Managing Director | NED Jul 2012; CEO 21 Oct 2013 | Executive | More than 30 years in medtech and pharma. Over a decade on Cochlear's executive team as SVP Global Marketing. BSc, MBA. |
Marie McDonald | NED; Chair of People & Culture, Safety and Remuneration Committee | 24 Oct 2016 | Independent | Former Ashurst partner; former member of the Takeovers Panel (2001–10). NED of Nufarm, Telix Pharmaceuticals and WEHI. |
Dr Tracey Batten | NED | 26 Sep 2023 | Independent | Former CEO of Imperial College Healthcare NHS Trust and St Vincent's Health Australia. NED of Medibank, EBOS and IHH Healthcare. MBBS, Harvard MBA. |
Dr Larry Marshall | NED; Chair of Innovation & Development Committee (from 5 Nov 2025) | 3 Oct 2023 | Independent | Former CSIRO Chief Executive (about 8.5 years); co-founder of six companies; NED of Fortescue. PhD (physics). |
Gerard Dalbosco | NED | 14 Jan 2025 | Independent | Former EY Oceania Managing Partner and CEO. NED of Medibank. FCA. |
Sarah Butler | NED | 20 Jan 2026 | Independent | Over 35 years in strategy consulting (Booz & Company MD Greater China; led PwC Global Health Services). NED of Australian Clinical Labs. |
Dr Lisa McIntyre | Former NED (ceased 5 Nov 2025) | 13 Dec 2019 | Independent | Formerly chaired the Innovation & Development Committee |
Executive Leadership Team
| Name | Title | Joined | Prior roles |
|---|---|---|---|
Michael Kavanagh | CEO & President, MD | Oct 2013 | Cochlear (SVP Global Marketing) |
Jason Burriss | Chief Financial Officer | 3 Oct 2023 | 15 years at GE, including CFO of GE Healthcare ANZ; CFO roles at Hilti (Dubai, Singapore). BCom, CA. |
Rod Lopez | Chief Operating Officer | Mar/Apr 2019 | 13 years at Cochlear, including Global Head of Manufacturing; GM Holden. MBA, BEng. |
Derek Minihane | Chief Technology Officer | Sep 2023 | VP R&D at Cochlear; partner at Deloitte; Silicon Valley semiconductors. BSEE, JD. |
Matthew Carbines | General Counsel & Company Secretary | Aug 2017 (Executive Team Oct 2021; Co. Sec. May 2023) | GC of a London software business. LLB, BCom. |
Jodi Sampson | Chief People & Culture Officer | Apr 2020 | HR Director at Samsung; Orange Business Services APAC |
Dr Jonathan Burdach | Chief Medical Affairs & Scientific Officer | 2012 (Executive Team Mar 2024) | Life-sciences consulting. PhD. |
Sunny Pillai | Chief Information Officer | Nov 2022 | ResMed (Head of Finance Systems; Senior Director Product Innovation) |
Bill (William) Haydon | Regional President, North America | 1 Dec 2025 | Avanos (Pain Management); Cantel Medical Division; Bayer; AGA Medical; Boston Scientific/SciMed. MBA (Carlson). |
Ronan Wright | Regional President, Europe and Middle East | 2019 | Pentax Medical, J&J/ASP, Wassenburg Medical (endoscope reprocessing). Based in Dublin. |
Kimberly Hill | Chief Marketing Officer and Regional President APAC | Aug 2025 | Medtronic, Getz Healthcare, Harrison.ai |
Board & Management Changes
| Date | Change |
|---|---|
Jan 2025 | Gerard Dalbosco joins the Board |
Aug 2025 | Kimberly Hill appointed CMO and Regional President APAC |
5 Nov 2025 | Dr Lisa McIntyre retires; Dr Larry Marshall becomes Chair of the Innovation & Development Committee |
1 Dec 2025 | Bill Haydon succeeds Ken Shaw (retired after more than eight years) as head of North America |
20 Jan 2026 | Sarah Butler joins the Board (bought 15,000 shares on 26 Feb 2026 for about A$51k) |
Major Shareholders
| Holder | Stake | Date / source |
|---|---|---|
UBS Group AG and related bodies corporate | 16,022,967 shares (5.30%) | Latest substantial-holder notice (InvestSMART). UBS first crossed 5% on 8 May 2026 with a 5.29% interest, held partly through stock borrowing and lending. |
Yarra Funds Management Limited | 16,009,579 shares (5.30%) | Substantial-holder register (InvestSMART) |
JPMorgan Chase & Co. | Ceased to be a substantial holder (below 5%) | 1 Jun 2026 notice |
Competitive Landscape
Key Competitors
| Competitor | Offering | Positioning vs Nanosonics |
|---|---|---|
Germitec (France, private) | Chronos UV-C automated HLD; about 90-second cycle; chemical-free | Received FDA De Novo (reported as August 2024). About 2,500 units in 40 countries; raised about US$75M including a US$30M Series B led by Eurazeo. The most direct automated, device-based challenger, with speed and "no chemicals" positioning. |
Tristel plc (UK, AIM: TSTL) | Tristel ULT chlorine-dioxide foam-and-wipe HLD with a 2-minute contact time; FDA cleared; Tristel Trio in Europe | Capital-free manual alternative. ANSI/AAMI ST58 now recognises chlorine-dioxide foam as HLD. The American College of Emergency Physicians (ACEP) ultrasound subcommittee reviewed ULT favourably in October 2025. Main threat is in point-of-care and emergency settings. |
CIVCO Medical Solutions | Probe reprocessing products: soaking stations, covers and disinfection systems | Incumbent in manual and soak workflows and probe accessories |
CS Medical | TEE probe reprocessors (e.g., TD-100) | Niche: transoesophageal probes |
Advanced Sterilization Products (ASP, Fortive) | HLD chemistries, sterilisers and disinfectants | Broad infection-prevention competitor (glutaraldehyde/OPA soak alternatives) |
Ecolab and other generic disinfectant suppliers | Manual HLD chemistries | Legacy manual methods that trophon displaced |
STERIS plc (incl. Cantel/Medivators) | Automated endoscope reprocessors (AERs), detergents, brushes, endoscopy consumables | Dominant US endoscopy reprocessing incumbent. CORIS addresses the cleaning step before HLD, so it can complement STERIS but also competes for budget and workflow. Nanosonics' new North America head comes from Cantel. |
Olympus Corporation | OER-series AERs and the scopes themselves | Scope OEM with reprocessing equipment. CORIS's initial De Novo indication is for an Olympus EVIS colonoscope family. Olympus is both a compatibility partner and a potential competitor. |
HOYA / PENTAX Medical (incl. Wassenburg Medical) | AERs, drying cabinets | European incumbent. Ronan Wright, Nanosonics' head of Europe, is ex-Wassenburg and ex-Pentax. |
Getinge | Endoscope washer-disinfectors and storage | European infection-control competitor |
Ruhof, Healthmark and similar | Manual cleaning brushes, enzymatic detergents, flushing aids | The status quo that CORIS aims to replace for channel cleaning |
Disposable / single-use endoscopes (e.g., Ambu, Boston Scientific EXALT-D) | Single-use scopes that eliminate reprocessing | A substitution threat over the long term |
Peer Comparison FY2026
| Metric | Nanosonics (FY26, A$) | STERIS (FY25, Mar YE, US$) | Tristel (FY24, Jun YE, £) | Olympus (FY25, Mar YE, ¥) |
|---|---|---|---|---|
Revenue | 203.9M | about 5.46B | about 41.9M | about 997B |
Revenue growth | +3% (+6% CC) | — | — | — |
Gross margin | 76.9% | — | — | — |
EBIT margin | 7.8% (trophon-only 24.8%) | — | — | — |
R&D / revenue | about 16% | — | — | — |
Recent Developments
--



